International: +1-347-960-6455
Female Contraception Therapeutics - Pipeline Analysis 2018

Female Contraception Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10131 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Others
Select License Type

Female contraception prevents unwanted or unintended pregnancy. When the matured egg cell leave the ovary and ovulation begins, the chances of becoming pregnant increases. The main advantage of using contraceptives is reduction in menstrual bleeding and period pain. Non-hormonal contraceptives have less side-effects in women as compared to hormonal contraceptives. Some of the disadvantages observed in women using hormonal contraceptives are sore breast, nausea, headache, and thrombosis. Agile Therapeutics Inc. is in the process of developing AG200 as an estrogen receptor agonist for female contraception. Viramal Limited is another key player developing therapeutics for female contraception related medical conditions.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.